Femasys, Inc. (FEMY)
NASDAQ:FEMY
Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$5.08 - $22.22
Previous CloseN/A
Volume25.00K
Average Volume (3M)85.81K
Market Cap
$16.28M
Enterprise Value$10.74M
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)$4.73M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 12, 2026EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume133,871
30 Day Avg. Volume85,813
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$1.50Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.53
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Commercial TractionConsistent multi-year revenue growth demonstrates early commercial uptake of FemVue and related consumables, indicating product-market fit in fertility diagnostics. Durable adoption by clinicians can produce repeat consumable revenue and support gradual scale, improving the path to sustainable operations if growth continues.
Healthy Product Gross MarginsSustained mid-to-high gross margins for medical consumables imply attractive unit economics and the ability to leverage incremental revenue into margin expansion. With scalable manufacturing, healthy gross margins create a realistic path to profitability as fixed SG&A and R&D are spread over higher sales volumes.
Strengthened Operational LeadershipHiring a seasoned med‑tech operations executive brings proven experience in scaling manufacturing, quality systems and global commercialization. This durable improvement in operational capability can accelerate execution, reduce supply‑chain risks, and improve gross margin and product rollout consistency over the medium term.
Bears Say
Severe Negative Cash GenerationSustained large negative operating and free cash flow creates ongoing financing needs and constrains reinvestment. Over months this forces management to prioritize fundraising or cost cuts, increases dilution risk, and limits the firm’s ability to self-fund commercialization or regulatory activities absent a material revenue inflection.
Very Large Operating And Net LossesOperating and net losses far exceed revenues, indicating a cost base that is not yet scalable relative to sales. Persistently negative margins reduce return potential, strain working capital and make achieving durable profitability dependent on significant top-line growth or structural cost reduction.
High Reliance On External Financing And Dilution RiskBoard-authorized financing mechanics and recent warrant issuances enable substantial equity dilution tied to lender conversions. This structural dependence on outside capital increases governance influence from financiers, risks future dilution for shareholders and signals limited near-term self-financing capacity absent rapid revenue scale.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $5.08 and its highest was $22.22 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $16.28M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 63 days.
How were Femasys, Inc.’s earnings last quarter?
Currently, no data Available
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -1.27.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 3,019,534 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
FEMY Stock 12 Month Forecast
Average Price Target
$1.50
▲(105.48% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
2.83% Insiders
2.62% Mutual Funds
11.06% Other Institutional Investors
81.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---